Organon LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$27Mgeneral payments (2019-2025)
$237Kresearch payments (2019-2025)
71,236clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Nexplanon $6.2M associated (2023-2025)
- Vtama $4.3M associated (2023-2025)
- Jada System $410K associated (2023-2025)
- Hadlima $211K associated (2023-2025)
- Renflexis $133K associated (2023-2025)
- Follistim Aq $88K associated (2023-2025)
- Ganirelix Acetate $73K associated (2023-2025)
- Pregnyl $63K associated (2023-2025)
- Nuvaring $14K associated (2023-2025)
- Ontruzant $9,852 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| R Ezekowitz | Boston, MA | Pediatrics | $1,332,304.81 |
| Philip Ozuah | Bronx, NY | Pediatrics | $1,003,896.03 |
| Edmund Kim | Lawrenceville, GA | Obstetrics & Gynecology | $368,410.44 |
| Michael Green | Oxnard, CA | Obstetrics & Gynecology | $271,009.05 |
| George Kuhn | Houston, TX | Obstetrics & Gynecology | $175,425.44 |
| Jamille Nagtalon-Ramos | Philadelphia, PA | Obstetrics & Gynecology (Nurse Practitioner) | $173,728.64 |
| William Coleman | Greenville, SC | Obstetrics & Gynecology | $169,775.87 |
| Paula Jasionowski | Voorhees, NJ | Obstetrics & Gynecology (Nurse Practitioner) | $167,967.20 |
| Camilo Gonima | San Antonio, TX | Obstetrics & Gynecology | $164,759.53 |
| Linda New | Lake Mary, FL | Physician Assistant | $162,800.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.